Globus Medical Inc. Class A Common Stock vs PepsiCo, Inc. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while PepsiCo, Inc. trades at $129.94 (market cap $173.48B). The key difference: PepsiCo, Inc. is far larger — about 16.9× Globus Medical Inc. Class A Common Stock's market cap, and PepsiCo, Inc. pays a 4.65% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and PepsiCo, Inc. for 108 Days on average.
| GMED | PEP | |
|---|---|---|
Market Cap | $10.25B | $173.48B |
Volume | 1,108,124 | 11,774,872 |
Sector | Health | Consumer Staples |
52-Week High | $96.82 | $170.44 |
52-Week Low | $58.33 | $123.64 |
Typical Hold Time | 0 Days | 108 Days |
Enterprise Value | $9.76B | $214.19B |
Dividend Yield | — | 4.65% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
PepsiCo (PEP) trades at $129.27, up 2.01% with strong earnings momentum as the company has beaten EPS estimates for four consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with $93.93B revenue and 11.09% net margin. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a cautious outlook with 67.4% hold ratings.
PEP offers stable dividend income and consistent profitability, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $142.38 suggests 10% upside potential, but technical weakness and mixed sentiment warrant careful monitoring of North American performance in upcoming earnings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →